Pharmaceutical Technology

AUGUST 22, 2022

When it comes to pharmaceutical, nutritional or cosmeceutical dosing, some of the most crucial parameters are safety, product effectiveness and patient adherence. They also offer enhanced bioavailability, exact dosing and an extended shelf life. The best formulation for the job.

Compliance 130

Compliance Bioavailability Containment Branding 130

Cloudbyz

MARCH 5, 2024

The difference between biologics vs small molecules in pharma drug development In pharmaceutical drug development, biologics and small molecules represent two distinct categories of medicinal products, each with their own unique characteristics, development processes, and mechanisms of action.

Development 97

Development Drugs Immune Response Manufacturing 97

The Pharma Data

JANUARY 5, 2021

Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. This is because many proteins do not have small-molecule binding sites. So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins. Most Read Today. Source link.

RNA 52

RNA Protein Bioavailability DNA 52

Roots Analysis

MAY 21, 2024

In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Delveinsight

FEBRUARY 16, 2021

With damages to the bone marrow, the production and normal functioning of red blood cells, white blood cells, and platelets get hampered. Padcev is a first-in-class antibody-drug conjugate (ADC) directed against Nectin-4, a protein. The therapy is the first therapy of its kind to target the Nectin-4 protein.

Marketing 52

Marketing Protein Bioavailability Drugs 52

XTalks

AUGUST 8, 2024

Dr. Dieterich elaborated on the critical aspects of each component: “There’s the protein part, a small molecule and then there’s the linker part in the middle.” Dieterich discussed the potential of applying ADC techniques to AOCs, which use oligonucleotides to interfere with mRNA and, thus, protein production.

Development 64

Development Medicine Antibody Protein 64

The Pharma Data

DECEMBER 9, 2020

Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets,” Feinberg said at the time of the launch. It’s like taking out the trash.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

NOVEMBER 22, 2020

About EZEPROGIND (AZP2006): Alzprotect is developing a drug candidate, EZEPROGIND, whose mode of action, acting on Progranulin secretion, is clearly different from other products developed in the past 15 years by the pharmaceutical industry. EZEPROGIND, which is kicking off phase 2a trials, is a bioavailable neurotrophic inducer.

Drugs 40

Drugs Protein Bioavailability Development 40

Delveinsight

JANUARY 7, 2021

It also slates to commence a Phase Ib trial of its second candidate, TERN-201, a vascular adhesion protein (VAP-1) inhibitor, with top-line data anticipated in the first half of 2022. Terns schedules to bring a third candidate into the clinic this year, TERN-501, a thyroid hormone receptor (THR) beta-agonist.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

Roots Analysis

MARCH 13, 2022

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. In fact, over 8,000 biological pharmaceutical products are currently under clinical investigation worldwide.

Manufacturing 52

Manufacturing Drug Delivery Marketing Drug Delivery Systems 52

Roots Analysis

OCTOBER 2, 2023

Owing to their unique size and physicochemical properties ( surface roughness, surface area, surface energy, crystal structure and shape ), nanoparticles can be widely used as a contrasting agent in medical imaging, a vesicle to cross the blood-brain barrier and a carrier for targeted delivery of genes / drugs, proteins, vaccines and antibiotics.

Drug Delivery 40

Drug Delivery Drugs Bioavailability Development 40

The Pharma Data

NOVEMBER 19, 2020

Program focused on inhibitors of SARS-CoV-2 main protease, a highly conserved protein essential for viral replication. These compounds have demonstrated high potency in inhibiting the activity of the M pro protease as well as promising oral bioavailability and blood plasma levels in animal studies.

Development 40

Development Bioavailability Production Drugs 40

Delveinsight

JULY 30, 2020

Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands. A novel, brain penetrant, orally bioavailable and selective PPAR?

Hormones 52

Hormones Marketing Gene Trials 52

XTalks

AUGUST 30, 2022

Global sales of over-the-counter and prescription products related to central nervous system (CNS) disease added up to $86 billion in 2019. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? Consider targeting your therapies that fail to be orally bioavailable and brain penetrant.

Trials 83

Trials Drug Delivery Drugs Gene 83

Pharmaceutical Technology

FEBRUARY 23, 2023

Quotient Sciences helps biotech and pharma customers in the development and optimization of drug products. How does bioavailability play a role in biopharmaceutics? Now fraction absorbed and bioavailability are often confused and used interchangeably.

Development 246

Development Drugs Bioavailability In-Vivo 246

XTalks

MARCH 24, 2025

Over time, this leads to proteinuria, where protein leaks into the urine, and eventually to kidney failure. Last month, the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion on Fabhalta for C3G. Regulatory reviews in China and Japan are underway.

Bioavailability 71

Bioavailability Immune Response Protein Bacteria 71